How does pneumonia occur

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: Pneumonia occurs when pathogens like bacteria, viruses, or fungi infect the lungs, causing inflammation in the alveoli. According to the WHO, it caused 14% of all deaths in children under 5 globally in 2019.

Key Facts

Pneumonia causes 2.5 million deaths annually, including 672,000 children under 5 (WHO, 2019)
Streptococcus pneumoniae is responsible for up to 50% of community-acquired bacterial pneumonia cases
Viral pneumonia accounts for about 20–30% of adult pneumonia cases
The flu virus can lead to secondary bacterial pneumonia within 48 hours of initial infection
Smokers are 4x more likely to develop pneumonia than non-smokers

Overview

Pneumonia is a respiratory infection that inflames the air sacs in one or both lungs, often filling them with fluid or pus. It can range from mild to life-threatening, particularly in infants, older adults, and people with weakened immune systems.

The condition develops when pathogens bypass the body’s natural defenses in the respiratory tract and colonize lung tissue. Risk factors such as age, smoking, and chronic illnesses increase susceptibility to infection.

Pathogens: Bacteria like Streptococcus pneumoniae cause the majority of bacterial pneumonia cases, especially in adults over 65.
Viral origins: Influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 are common viral causes of pneumonia, particularly during flu season.
Fungal sources: Fungi such as Pneumocystis jirovecii primarily affect immunocompromised individuals, including those with HIV/AIDS.
Transmission: Pneumonia spreads through airborne droplets when infected individuals cough or sneeze, making crowded environments high-risk.
Incubation: Symptoms typically appear 1–3 days after exposure for bacterial pneumonia, but up to 10 days for viral forms.

How It Works

The development of pneumonia involves a breakdown in the body’s respiratory defenses, allowing pathogens to invade lung tissue and trigger inflammation. This process disrupts gas exchange and leads to characteristic symptoms like cough, fever, and shortness of breath.

Inhalation of pathogens:Over 90% of pneumonia cases begin when microbes are inhaled into the lower respiratory tract from contaminated air or saliva.
Mucociliary clearance failure: The respiratory tract’s mucus and cilia normally trap and expel invaders, but smoking or illness can impair this first-line defense.
Alveolar invasion: Pathogens reach the alveoli, where they multiply and trigger an immune response, leading to inflammation and fluid buildup.
Immune response: White blood cells flood the area, causing pus formation and reducing oxygen transfer efficiency in the lungs.
Systemic effects: Cytokines released during inflammation can cause fever, chills, and fatigue, even affecting organs beyond the lungs.
Secondary complications: Untreated pneumonia can lead to pleural effusion or sepsis, with mortality rates exceeding 30% in severe cases.

Comparison at a Glance

The following table compares common types of pneumonia by cause, prevalence, treatment, and at-risk groups.

Type	Primary Cause	Annual Cases (Global)	Treatment	High-Risk Groups
Bacterial	Streptococcus pneumoniae	450 million	Antibiotics	Adults over 65, smokers
Viral	Influenza, RSV	200 million	Antivirals, supportive care	Children under 2, elderly
Fungal	Pneumocystis jirovecii	500,000	Antifungals	HIV patients, immunocompromised
Aspiration	Inhalation of food or stomach contents	10% of hospital-acquired cases	Antibiotics, suction	Stroke patients, sedated individuals
Walking	Mycoplasma pneumoniae	1 in 20 pneumonia cases	Macrolide antibiotics	Young adults, school-aged children

Understanding these differences helps guide diagnosis and treatment. For example, bacterial pneumonia often requires immediate antibiotics, while viral forms may only need symptom management. Accurate identification prevents antibiotic overuse and improves outcomes.

Why It Matters

Pneumonia remains a leading cause of death worldwide, particularly in low-resource settings where access to vaccines and antibiotics is limited. Public health initiatives aim to reduce mortality through vaccination and improved diagnostics.

Vaccination: The PCV13 and PPSV23 vaccines prevent pneumococcal disease and are recommended for children and adults over 65.
Global burden: Pneumonia accounts for 14% of all under-5 deaths, making it the single largest infectious cause of child mortality.
Antibiotic resistance: Up to 30% of pneumococcal strains show resistance to penicillin in some regions, complicating treatment.
Healthcare costs: In the U.S., pneumonia leads to over 1 million hospitalizations annually, costing $10 billion in care.
Prevention: Simple measures like handwashing, mask-wearing, and smoking cessation reduce transmission risk significantly.
Climate impact: Air pollution increases susceptibility, with PM2.5 exposure linked to a 20% higher pneumonia risk in children.

Addressing pneumonia requires a multifaceted approach combining medical, environmental, and educational strategies to protect vulnerable populations and reduce global health disparities.